Evidence map›Paper›PMID 38256516›Full record

ArticleJournal of clinical medicine2024

Nine-Month Continuous Fremanezumab Prophylaxis on the Response to Triptans and Also on the Incidence of Triggers, Hypersensitivity and Prodromal Symptoms of Patients with High-Frequency Episodic Migraine.

Emmanouil V Dermitzakis, Michail Vikelis, Georgia Xiromerisiou, Dimitrios Rallis, Panagiotis Soldatos, Pantelis Litsardopoulos, Dimitrios Rikos, Andreas A Argyriou

Open access · goldAbstract read
In one paragraph

Article in Journal of clinical medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 6 institutions in 1 country.

Emmanouil V DermitzakisEuromedica General Clinic, 54645 Thessaloniki, Greece.ORCID 0000-0001-9275-0076
Michail VikelisHeadache Clinic, Mediterraneo Hospital, 16675 Athens, Greece.ORCID 0000-0002-2715-7898
Georgia XiromerisiouDepartment of Neurology, University Hospital of Larissa, University of Thessaly, 41110 Larissa, Greece.ORCID 0000-0001-7162-3588
Dimitrios RallisDepartment of Neurology, Tzaneio General Hospital of Piraeus, 18536 Athens, Greece.
Panagiotis SoldatosIndependent Researcher, 24100 Kalamata, Greece.
Pantelis LitsardopoulosHeadache Outpatient Clinic, Department of Neurology, Agios Andreas State General Hospital of Patras, 26335 Patras, Greece.
Dimitrios Rikos404 Military Hospital, 41222 Larisa, Greece.ORCID 0000-0003-2346-5057
Andreas A ArgyriouHeadache Outpatient Clinic, Department of Neurology, Agios Andreas State General Hospital of Patras, 26335 Patras, Greece.ORCID 0000-0003-2131-7114
Agios Andreas Hospital · GR404 General Military Hospital · GREuromedica · GRKAT General Hospital of Attica · GRTzaneion General Hospital · GRUniversity of Thessaly · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

effectsfremanezumabhypersensitivity symptomsprodromal symptomsresponse to triptanstriggers

Identifiers

PMID38256516
PMCPMC10816996
OpenAlexW4390704205

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.